<code id='1E967BC773'></code><style id='1E967BC773'></style>
    • <acronym id='1E967BC773'></acronym>
      <center id='1E967BC773'><center id='1E967BC773'><tfoot id='1E967BC773'></tfoot></center><abbr id='1E967BC773'><dir id='1E967BC773'><tfoot id='1E967BC773'></tfoot><noframes id='1E967BC773'>

    • <optgroup id='1E967BC773'><strike id='1E967BC773'><sup id='1E967BC773'></sup></strike><code id='1E967BC773'></code></optgroup>
        1. <b id='1E967BC773'><label id='1E967BC773'><select id='1E967BC773'><dt id='1E967BC773'><span id='1E967BC773'></span></dt></select></label></b><u id='1E967BC773'></u>
          <i id='1E967BC773'><strike id='1E967BC773'><tt id='1E967BC773'><pre id='1E967BC773'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:comprehensive    Page View:8
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In